"The U.S. Food and Drug Administration today approved Vimizim (elosulfase alfa), the first FDA-approved treatment for Mucopolysaccharidosis Type IVA (Morquio A syndrome). Morquio A syndrome is a rare, autosomal recessive lysosomal storage disease "...
(Generic versions may still be available.)
Patients should be advised that cinoxacin may be taken with or without meals. Patients should drink fluids liberally. Antacids containing magnesium or aluminum, as well as sucralfate, metal cations such as iron, and multivitamin preparations with zinc or VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution may interfere with the gastrointestinal absorption of cinoxacin. These agents should be taken at least 2 hours before or 2 hours after cinoxacin administration.
Patients should be advised to avoid excessive sunlight during cinoxacin therapy. If phototoxicity occurs, cinoxacin therapy should be discontinued.
Cinoxacin can cause dizziness and light-headedness; therefore, patients should know how they react to the drug before operating an automobile or machinery or engaging in an activity requiring mental alertness or coordination.
Patients should be advised that convulsions have been reported in patients taking quinolones, including cinoxacin acid, and to notify their physician before taking this drug if there is a history of this condition.
Patients should be advised that cinoxacin may increase the effects of theophylline and caffeine. There is a possibility of caffeine accumulation when products containing caffeine are consumed during cinoxacin therapy.
Last reviewed on RxList: 12/8/2004
This monograph has been modified to include the generic and brand name in many instances.
Additional Cinobac Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.